---
document_datetime: 2024-11-28 14:26:29
document_pages: 94
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/comirnaty-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: comirnaty-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 51.5768369
conversion_datetime: 2025-12-18 23:50:03.272648
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## COMIRNATY

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                       | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                                                                                                                                                                                  |
|----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0220/G            | This was an application for a group of variations. A grouped application comprised of 2 Type II Variations as follows: C.I.4 - Change(s) in the SPC, Labelling or PL due to | 19/09/2024                          |                                             | SmPC                             | Update of sections 4.8 and 5.1 of the SmPC in order to update safety and immunogenicity information based on interim results from interventional study C4591048 substudy B and substudy D listed as a category 3 study in the RMP; C4591048 is a master phase 1/2/3 study to investigate the safety, tolerability, and immunogenicity of |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                     | new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                 |            |            |                     | Comirnaty Original/Omi BA.4/BA.5 in healthy children. Update of section 4.9 of the SmPC in order to update safety information based on post-marketing data related to overdose.   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0219/G           | This was an application for a group of variations. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority | 12/09/2024 | n/a        |                     |                                                                                                                                                                                   |
| II/0217             | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                  | 05/09/2024 | n/a        |                     |                                                                                                                                                                                   |
| PSUSA/10898 /202312 | Periodic Safety Update EU Single assessment - tozinameran (COMIRNATY), tozinameran/riltozinameran (COMIRNATY Original/Omicron BA.1), tozinameran/famtozinameran (COMIRNATY Original/Omicron BA.4-5), raxtozinameran (COMIRNATY Omicron XBB.1.5)                                                                                                | 11/07/2024 | n/a        |                     | PRAC Recommendation - maintenance                                                                                                                                                 |
| II/0216             | B.I.a.6.a - Changes to the active substance of a vaccine against human coronavirus - Replacement or addition of a serotype, strain, antigen or coding                                                                                                                                                                                          | 27/06/2024 | 03/07/2024 | SmPC, Labelling and | Addition of a new strain (Omicron JN.1, bretovameran) resulting in nine new monovalent presentations. For more information, please refer to the Summary of                        |

<div style=\"page-break-after: always\"></div>

|           | sequence or combination of serotypes, strains, antigens or coding sequences for a human coronavirus vaccine                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |            |     | PL   | Product Characteristics.   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------|----------------------------|
| IB/0218/G | This was an application for a group of variations. B.II.z - Quality change - Finished product - Other variation B.I.z - Quality change - Active substance - Other variation B.I.z - Quality change - Active substance - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 25/06/2024 | n/a |      |                            |
| II/0206/G | This was an application for a group of variations. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority | 13/06/2024 | n/a |      |                            |

<div style=\"page-break-after: always\"></div>

| IB/0215/G   | This was an application for a group of variations. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.II.z - Quality change - Finished product - Other variation B.I.z - Quality change - Active substance - Other variation                                                                                                                                                                                                                                                                                               | 31/05/2024   | n/a        |                        |                                                                                                                                                                                                                                          |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0201     | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 30/05/2024   | 03/07/2024 | SmPC and PL            | Comirnaty may be administered concomitantly with seasonal influenza vaccine. Different injectable vaccines should be given at different injection sites.                                                                                 |
| II/0212/G   | This was an application for a group of variations. B.II.b.3.c - Change in the manufacturing process of the finished or intermediate product - The product is a biological/immunological medicinal product and the change requires an assessment of comparability B.II.e.1.b.2 - Change in immediate packaging of the finished product - Change in type/addition of a new container - Sterile medicinal products and biological/immunological medicinal products B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits | 16/05/2024   | 03/07/2024 | SmPC, Labelling and PL | The SmPC has been updated to introduce the new presentation COMIRNATY Omicron XBB.1.5 30 micrograms/dose dispersion for injection in a pre-filled syringe (glass), EU/1/20/1528/027. The Labelling and PL have been updated accordingly. |
| IB/0214/G   | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor                                                                                                                                                                                                                                                                                                                                                                                                                                               | 15/05/2024   | n/a        |                        |                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

|           | changes to an approved test procedure B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation                                                  |            |            |                        |                                                                                                                                                                                                                                                                                                                                                                                                                   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0213/G | This was an application for a group of variations. C.I.7.z - Deletion of formulation C.I.7.z - Deletion of formulation                                                                         | 15/05/2024 | 03/07/2024 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                   |
| X/0199    | Annex I_2.(c) Change or addition of a new strength/potency                                                                                                                                     | 21/03/2024 | 15/05/2024 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                   |
| IB/0210   | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                  | 03/04/2024 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                   |
| II/0205   | B.II.e.1.b.2 - Change in immediate packaging of the finished product - Change in type/addition of a new container - Sterile medicinal products and biological/immunological medicinal products | 14/03/2024 | 15/05/2024 | SmPC, Labelling and PL | Change in the immediate packaging of the finished product COMIRNATY Omicron XBB.1.5 30 micrograms/dose dispersion for injection to introduce a single-dose prefilled syringe presentation (EU/1/20/1528/025). The SmPC sections 1, 2, 4.2, 6.3, 6.5, 6.6 has been updated to include information about pre-filled syringe . The Labelling and PL have been updated accordingly.                                   |
| II/0203   | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                              | 14/03/2024 | 15/05/2024 | SmPC                   | Update of section 4.8 of the SmPC in order to update the safety information based on interim (6 months post-dose 3 in paediatric population aged between 6 months - 12 years old) results from study C4591007, listed as a category 3 study in the RMP. This is an interventional \"phase 1, open- label dose-finding study to evaluate safety, tolerability, and immunogenicity and phase 2/3 placebo-controlled, |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |     | observer-blinded safety, tolerability, and immunogenicity study of a sars-cov-2 RNA vaccine candidate against COVID-19 in healthy children.   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0209/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.II.c.z - Change in control of excipients in the Finished Product - Other variation B.II.c.z - Change in control of excipients in the                                                                      | 05/03/2024 | n/a |                                                                                                                                               |
| II/0202   | B.I.z - Quality change - Active substance - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 29/02/2024 | n/a |                                                                                                                                               |
| IB/0208/G | This was an application for a group of variations. B.II.e.7.a - Change in supplier of packaging components or devices (when mentioned in the dossier) - Deletion of a supplier B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.II.e.7.b - Change in supplier of packaging | 26/02/2024 | n/a |                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

|           | dossier) - Replacement or addition of a supplier                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |            |     |                                                                  |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------------------------------------------------------------|
| IB/0207/G | group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.II.c.z - Change in control of excipients in the                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 21/02/2024 | n/a | This was an application for a Finished Product - Other variation |
| II/0197/G | This was an application for a group of variations. B.I.b.1.g - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Widening of the approved specs for starting mat./intermediates, which may have a significant effect on the quality of the AS and/or the FP B.I.z - Quality change - Active substance - Other variation B.I.b.1.g - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Widening of the approved specs for starting mat./intermediates, which may have a significant effect on the quality of the AS and/or the FP B.I.b.1.g - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Widening of the | 11/01/2024 | n/a | approved specs for starting                                      |

<div style=\"page-break-after: always\"></div>

|                     | which may have a significant effect on the quality of the AS and/or the FP                                                                                                                                                                                                                                                     |            |     |                                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| II/0194             | Submission of the final report from study C4591014 listed as a category 3 study in the RMP. This is a retrospective database study to evaluate the effectiveness of COVID-19 BNT162b2 vaccine in a real-world setting. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission | 11/01/2024 | n/a |                                   |
| PSUSA/10898 /202306 | Periodic Safety Update EU Single assessment - tozinameran (COMIRNATY), tozinameran/riltozinameran (COMIRNATY Original/Omicron BA.1), tozinameran/famtozinameran (COMIRNATY Original/Omicron BA.4-5), raxtozinameran (COMIRNATY Omicron XBB.1.5)                                                                                | 11/01/2024 | n/a | PRAC Recommendation - maintenance |
| II/0192             | B.II.b.4.c - Change in the batch size (including batch size ranges) of the finished product - The change requires assessment of the comparability of a biological/immunological medicinal product or a new bioequivalence study                                                                                                | 14/12/2023 | n/a |                                   |
| IB/0200/G           | This was an application for a group of variations. B.I.z - Quality change - Active substance - Other variation B.I.z - Quality change - Active substance - Other                                                                                                                                                               | 12/12/2023 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

|           | variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |            |            |                        |                                                                   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------------------------------------------------------------|
| IB/0191/G | This was an application for a group of variations. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 05/12/2023 | 15/05/2024 | SmPC, Labelling and PL |                                                                   |
| IB/0196/G | This was an application for a group of variations. B.I.z - Quality change - Active substance - Other variation B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.2.b - Change in test procedure for AS or starting material/reagent/intermediate - Deletion of a test procedure for the AS or a starting material/reagent/intermediate, if an alternative test procedure is already authorised A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.z - Quality change - Active substance - Other variation procedure for AS or | 22/11/2023 | n/a        |                        | B.I.b.2.a - Change in test starting material/reagent/intermediate |

<div style=\"page-break-after: always\"></div>

|           | changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |            |            |      |                                                                        |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|------------------------------------------------------------------------|
| IB/0198   | B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 17/11/2023 | 29/11/2023 | SmPC |                                                                        |
| IB/0195/G | This was an application for a group of variations. B.II.z - Quality change - Finished product - Other variation B.II.c.1.c - Change in the specification parameters and/or limits of an excipient - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.II.c.2.d - Change in test procedure for an excipient - Other changes to a test procedure (including replacement or addition) B.II.c.2.d - Change in test procedure for an excipient - Other changes to a test procedure (including replacement or addition) B.II.c.2.d - Change in test procedure for an excipient - Other changes to a test procedure (including | 26/10/2023 | n/a        |      |                                                                        |
| II/0188/G | This was an application for a group of variations. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing                                                                                                                                                                                                                                                                                                                                                                                                         | 26/10/2023 | 29/11/2023 | SmPC | Please refer to Scientific Discussion 'Comirnaty-H-C- 005735-II-188-G' |

<div style=\"page-break-after: always\"></div>

|           | authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |            |            |                       |                                                                                                                                                                        |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0187   | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 26/10/2023 | n/a        |                       |                                                                                                                                                                        |
| IB/0190/G | This was an application for a group of variations. B.I.z - Quality change - Active substance - Other variation A.7 - Administrative change - Deletion of manufacturing sites B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites B.I.z - Quality change - Active substance - Other variation A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release B.I.z - Quality change - Active substance - Other variation A.7 - Administrative change - Deletion of manufacturing sites | 04/10/2023 | 19/10/2023 | SmPC, Annex II and PL | To extend the shelf life of COMIRNATY Original/Omicron BA.4-5 (1.5/1.5 Âµg)/dose concentrate for dispersion for injection (EU/1/20/1528/017) from 18 months to 2 years. |

<div style=\"page-break-after: always\"></div>

|           | manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites B.I.z - Quality change - Active substance - Other variation B.I.z - Quality change - Active substance - Other variation A.7 - Administrative change - Deletion of manufacturing sites B.I.z - Quality change - Active substance - Other variation A.7 - Administrative change - Deletion of manufacturing sites B.I.z - Quality change - Active substance - Other variation B.II.f.z - Stability of FP - Other variation   |            |            |       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0186/G | This was an application for a group of variations. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                             | 14/09/2023 | n/a        |       | Studies WI235284 (Emory) and WI255886 (Bristol) were conducted in hospital settings in the United States (May 2021 - August 2022) and The United Kingdom (January 2021 - August 2022), respectively. The overall vaccine effectiveness in the Bristol and Emory studies were 81.7% (95% CI: 77.1%, 85.4%) and 64.1% (95% CI: 51.3%, 73.5%), respectively. The studies found that two doses of Comirnaty provided a robust protection against COVID19- mediated acute respiratory infection during the Alpha- and Delta-waves but the vaccine effectiveness decreased during the Omicron-wave. |
| II/0183   | B.I.a.6.a - Changes to the active substance of a                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 30/08/2023 | 31/08/2023 | SmPC, | Please refer to Scientific Discussion 'Comirnaty-H-C-                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

|                     | vaccine against human coronavirus - Replacement or addition of a serotype, strain, antigen or coding sequence or combination of serotypes, strains, antigens or coding sequences for a human coronavirus vaccine                                                                                                                                                                                                                                                                                                                                                                             |            |            | Labelling and PL       | 005735-II-0183'                                                                                                                                       |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10898 /202212 | Periodic Safety Update EU Single assessment - tozinameran (COMIRNATY), tozinameran/riltozinameran (COMIRNATY Original/Omicron BA.1), tozinameran/famtozinameran (COMIRNATY Original/Omicron BA.4-5), raxtozinameran (COMIRNATY Omicron XBB.1.5)                                                                                                                                                                                                                                                                                                                                              | 20/07/2023 | 29/08/2023 | SmPC and PL            | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10898/202212.            |
| X/0180              | Annex I_2.(d) Change or addition of a new pharmaceutical form                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 22/06/2023 | 08/08/2023 | SmPC, Labelling and PL | Please refer to Scientific Discussion 'Comirnaty-H-C- 005735-X-0180'                                                                                  |
| II/0177/G           | This was an application for a group of variations. C.I.6.a: Extension of indication to include Comirnaty Original/Omicron BA.4-5 (5/5 micrograms)/dose concentrate for dispersion for injection and Comirnaty Original/Omicron BA.4-5 (15/15 micrograms)/dose dispersion for injection for use as primary vaccination course against COVID-19 in children aged 5 to 11 years and in individuals 12 years of age and older, respectively, based on interim results from studies C4591044 and C4591048. Study C4591044 is an interventional, randomized, active-controlled, phase 2/3 study to | 22/06/2023 | 08/08/2023 | SmPC, Labelling and PL | Please refer to Scientific Discussion 'Comirnaty-H-C- 005735-II-0177/G' For more information, please refer to the Summary of Product Characteristics. |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|        | immunogenicity of bivalent BNT162b RNA-based vaccine candidates as a booster dose in COVID-19 vaccine-experienced healthy individuals, while study C4591048 is a phase 1/2/3 master study to investigate the safety, tolerability, and immunogenicity of bivalent BNT162b2 RNA-based vaccine candidates in healthy children. As a consequence, sections 4.1, 4.2, 4.8, and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 10 of the RMP has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the product information. A.6: Change of the ATC Code of tozinameran, riltozinameran and famtozinameran from J07BX03 to J07BN01. In addition, the vaccine posology has been simplified for all approved formulations. As a consequence, sections 4.2, 4.4, 6.6 of the SmPC are updated. The Package Leaflet is updated in accordance. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one   |            |            |                     |                                                                      |
|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|---------------------|----------------------------------------------------------------------|
| X/0176 | Annex I_2.(c) Change or addition of a new strength/potency                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 22/06/2023 | 08/08/2023 | SmPC, Labelling and | Please refer to Scientific Discussion 'Comirnaty-H-C- 005735-X-0176' |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                            |            |            | PL   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0185   | B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol                                                        | 05/07/2023 | 17/07/2023 | SmPC | To extend the shelf-life of the biological finished product COMIRNATY 30 Î¼g Concentrate for dispersion for injection (EU/1/20/1528/001) from 18 months to 24 months when stored at the storage condition of -90 to -60 Â°C.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| IB/0184   | B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol                                                        | 05/07/2023 | 17/07/2023 | SmPC | To extend the shelf-life from 18 to 24 months when stored at the storage condition of -90 to -60 Â°C of the following biological finished product: COMIRNATY 30 Î¼g dispersion for injection (EU/1/20/1528/002-003) COMIRNATY 10 Î¼g concentrate for dispersion for injection (EU/1/20/1528/004-005) COMIRNATY Original/Omicron BA.1, 15/15 Î¼g dispersion for injection (EU/1/20/1528/006-007) COMIRNATY Original/Omicron BA.4-5, 15/15 Î¼g dispersion for injection (EU/1/20/1528/008-009) COMIRNATY 3 Î¼g concentrate for dispersion for injection (EU/1/20/1528/010) COMIRNATYOriginal/Omicron BA.4-5, 5/5 Î¼g concentrate for dispersion for injection (EU/1/20/1528/011-012) COMIRNATY 30 Î¼g dispersion for injection (EU/1/20/1528/013)- single dose vials COMIRNATY Original/Omicron BA.4-5 15/15 Î¼g dispersion for injection (EU/1/20/1528/014)- single dose vials |
| II/0182/G | This was an application for a group of variations. B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.z - Quality change - Finished product - Other | 22/06/2023 | n/a        |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

|           | B.II.z - Quality change - Finished product - Other variation B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation B.II.b.3.c - Change in the manufacturing process of the finished or intermediate product - The product is a biological/immunological medicinal product and the change requires an assessment of comparability B.II.b.3.c - Change in the manufacturing process of the finished or intermediate product - The product is a biological/immunological medicinal product and the change requires an assessment of comparability B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process   |            |     | variation   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------|
| II/0181   | B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 22/06/2023 | n/a |             |
| II/0178   | B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 01/06/2023 | n/a |             |
| II/0174/G | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 04/05/2023 | n/a |             |

<div style=\"page-break-after: always\"></div>

|           | control of excipients in the Finished Product - Other variation B.II.c.2.a - Change in test procedure for an excipient - Minor changes to an approved test procedure B.II.c.4.a - Change in synthesis or recovery of a non- pharmacopoeial or novel excipient - Minor change A.7 - Administrative change - Deletion of manufacturing sites                         |            |     | B.II.c.z - Change in   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------------------|
| IB/0179/G | This was an application for a group of variations. B.II.c.3.a.2 - Change in source of an excipient or reagent with TSE risk - From TSE risk material to vegetable or synthetic origin - For excipients or reagents USED in the manufacture of a biol/immunol AS or in a biol/immunol medicinal product B.I.z - Quality change - Active substance - Other variation | 13/04/2023 | n/a |                        |
| IB/0172/G | This was an application for a group of variations. B.I.d.z - Stability of AS - Other variation of AS - Other variation                                                                                                                                                                                                                                             | 04/04/2023 | n/a | B.I.d.z - Stability    |
| II/0167   | B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes                                                                 | 16/03/2023 | n/a |                        |

<div style=\"page-break-after: always\"></div>

| IB/0173/G   | This was an application for a group of variations. B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                                                                                                                                         | 13/03/2023   | n/a        |      |                                                                                                                                                                                                                        |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0171/G   | This was an application for a group of variations. B.II.z - Quality change - Finished product - Other variation B.II.z - Quality change - Finished product - Other variation B.I.z - Quality change - Active substance - Other variation B.I.z - Quality change - Active substance - Other variation B.I.z - Quality change - Active substance - Other variation B.I.z - Quality change - Active substance - Other variation B.I.z - Quality change - Active substance - Other variation B.I.z - Quality change - Active substance - Other variation | 13/03/2023   | n/a        |      |                                                                                                                                                                                                                        |
| II/0139     | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                                    | 23/02/2023   | 09/03/2023 | SmPC | No new safety concerns have been identified; the overall safety results are in line with data previously presented. Immunogenicity data 1 month after booster dose are updated due to neutralization assay validation. |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                             |            |            |                        | For more information, please refer to the Summary of Product Characteristics.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0160   | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                           | 09/02/2023 | 06/03/2023 | SmPC, Labelling and PL | Pre-specified hypothesis-driven efficacy analysis was performed with additional confirmed COVID 19 cases accrued during blinded placebo-controlled follow-up, representing up to 6 months after Dose 2 in the efficacy population. In the efficacy analysis of Study 3 in children 5 to 11 years of age without evidence of prior infection, there were 10 cases in 2,703 participants who received the vaccine and 42 cases out of 1,348 who received placebo. The point estimate for efficacy is 88.2% (95% confidence interval 76.2, 94.7) during the period when Delta variant was the predominant circulating strain. In participants with or without evidence of prior infection there were 12 cases in the 3,018 who received vaccine and 42 cases in 1,511 participants who received placebo. The point estimate for efficacy is 85.7% (95% confidence interval 72.4, 93.2). No new safety concerns have been identified; the overall safety results are in line with data previously presented. For more information, please refer to the Summary of Product Characteristics. |
| II/0165/G | This was an application for a group of variations. B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing | 16/02/2023 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

|           | processes B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change   |            |     |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IB/0170/G | This was an application for a group of variations. B.II.c.2.a - Change in test procedure for an excipient - Minor changes to an approved test procedure B.II.c.2.b - Change in test procedure for an excipient - Deletion of a test procedure if an alternative test procedure is already authorised B.II.c.z - Change in control of excipients in the Finished Product - Other variation B.II.c.2.d - Change in test procedure for an excipient - Other changes to a test procedure (including                                                                                                                                                                                                                                                                                                  | 07/02/2023 | n/a |

<div style=\"page-break-after: always\"></div>

|           | replacement or addition)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |            |            |             |                                                                                                                                                                                                                 |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0169   | B.I.z - Quality change - Active substance - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 30/01/2023 | n/a        |             |                                                                                                                                                                                                                 |
| II/0152   | C.I.3.b - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Change(s) with new additional data submitted by the MAH                                                                                                                                                                                                                                                                                 | 12/01/2023 | 30/01/2023 | SmPC and PL | Update of section 4.8 of the SmPC in order to add 'Dizziness' to the list of adverse drug reactions (ADRs) with frequency 'Uncommon', based on a cumulative review. The Package Leaflet is updated accordingly. |
| IB/0164/G | This was an application for a group of variations. B.I.z - Quality change - Active substance - Other variation B.I.z - Quality change - Active substance - Other variation B.I.d.z - Stability of AS - Other variation                                                                                                                                                                                                                                                                                                 | 16/01/2023 | n/a        |             |                                                                                                                                                                                                                 |
| II/0159/G | This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing | 12/01/2023 | n/a        |             |                                                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

|                     | B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.e.4.c - Change in shape or dimensions of the container or closure (immediate packaging) - Sterile medicinal products   |            |            |      |                                                                                                                                                                                   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10898 /202206 | Periodic Safety Update EU Single assessment - tozinameran (COMIRNATY), tozinameran/riltozinameran (COMIRNATY Original/Omicron BA.1), tozinameran/famtozinameran (COMIRNATY Original/Omicron BA.4-5), raxtozinameran (COMIRNATY Omicron XBB.1.5)                                                                                                                           | 12/01/2023 | n/a        |      | PRAC Recommendation - maintenance                                                                                                                                                 |
| IB/0166             | B.II.c.z - Change in control of excipients in the Finished Product - Other variation                                                                                                                                                                                                                                                                                      | 04/01/2023 | n/a        |      |                                                                                                                                                                                   |
| IB/0168             | B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol                                                                                                                                                                                       | 21/12/2022 | 22/12/2022 | SmPC | Shelf life extension of the finished product (Comirnaty 30 Âµg Concentrate for dispersion for injection, EU/1/20/1528/001) from 15 months to 18 months when stored at -90 to -60Â°C |
| IB/0161             | B.II.z - Quality change - Finished product - Other variation                                                                                                                                                                                                                                                                                                              | 13/12/2022 | n/a        |      |                                                                                                                                                                                   |
| N/0158              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                          | 08/12/2022 | n/a        |      |                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

| II/0156/G   | This was an application for a group of variations. B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.e.5.c - Change in pack size of the finished product - Change in the fill weight/fill volume of sterile multidose (or single-dose, partial use) parenteral medicinal products, including biological/immunological medicinal products B.II.e.5.c - Change in pack size of the finished product - Change in the fill weight/fill volume of sterile multidose (or single-dose, partial use) parenteral medicinal products, including biological/immunological medicinal products                        | 08/12/2022   | 22/12/2022   | SmPC, Labelling and PL   | The scope of this variation is to introduce a single dose vial (SDV) presentation. Sufficient data are provided to demonstrate that the single dose vial presentation is comparable to the currently approved multi dose presentations. The Product Information is updated as follows; Comirnaty, 30 micrograms/dose, dispersion for injection: The SmPC sections 2, 4.2, 6.3, 6.5 and 6.6 are updated to include information on single dose vials. Comirnaty Original/Omicron BA.4-5, (15/15 micrograms)/dose, dispersion for injection: The SmPC sections 2, 4.2, 6.3, 6.5 and 6.6 are updated to include information on single dose vials. The Labelling and PL have been updated accordingly.   |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0149/G   | This was an application for a group of variations. B.II.z - Quality change - Finished product - Other variation B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.II.e.7.a - Change in supplier of packaging components or devices (when mentioned in the dossier) - Deletion of a supplier B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.II.b.3.c - Change in the manufacturing process of the finished or intermediate product - The product is a biological/immunological medicinal product and the | 08/12/2022   | n/a          |                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

|           | change requires an assessment of comparability                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |            |            |             |                                                                                                                                                                                                               |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0148/G | This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.b.2.c - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure for a reagent, which does not have a significant effect on the overall quality of the AS B.I.z - Quality change - Active substance - Other variation B.I.b.1.g - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Widening of the approved specs for starting mat./intermediates, which may have a significant effect on the quality of the AS and/or the FP B.I.b.1.z - Change in the specification parameters | 08/12/2022 | n/a        |             |                                                                                                                                                                                                               |
| IAIN/0163 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 02/12/2022 | 02/12/2022 | SmPC and PL | To update section 4.8 of the SmPC and section 4 of the PL to implement the signal recommendation on heavy menstrual bleeding.                                                                                 |
| IB/0162/G | This was an application for a group of variations. B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 02/12/2022 | 02/12/2022 | SmPC        | To update the product information to extend the shelf life of the finished product from 12 months to 18 months when stored at the storage condition of -90 to -60 Â°C, for presentations EU/1/20/1528/002-012. |

<div style=\"page-break-after: always\"></div>

|           | medicinal product in accordance with an approved stability protocol B.II.f.1.e - Stability of FP - Change to an approved stability protocol B.II.f.1.e - Stability of FP - Change to an approved stability protocol                                                                                                                                                                                                             |            |     |                      |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------------------|
| IB/0157/G | This was an application for a group of variations. B.II.b.5.a - Change to in-process tests or limits applied during the manufacture of the finished product - Tightening of in-process limits B.II.z - Quality change - Finished product - Other variation B.II.z - Quality change - Finished product - Other variation B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change | 28/11/2022 | n/a | in the manufacturing |
| IB/0154   | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                                                                                                                                                                                                            | 16/11/2022 | n/a |                      |
| IB/0155/G | This was an application for a group of variations. B.I.z - Quality change - Active substance - Other variation B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS change - Active substance - Other                                                                                                                                                               | 15/11/2022 | n/a | B.I.z - Quality      |

<div style=\"page-break-after: always\"></div>

|           | variation                                                                                                                                                                                                                                                                                                                                                                                                                                                           |            |            |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0153/G | This was an application for a group of variations. B.I.z - Quality change - Active substance - Other variation A.7 - Administrative change - Deletion of manufacturing sites B.I.z - Quality change - Active substance - Other variation B.I.z - Quality change - Active substance - Other variation                                                                                                                                                                | 14/11/2022 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| X/0147    | Annex I_2.(c) Change or addition of a new strength/potency                                                                                                                                                                                                                                                                                                                                                                                                          | 10/11/2022 | 10/11/2022 | SmPC, Labelling and PL | Please refer to Scientific Discussion 'Comirnaty/H/C/005735/X/0147'                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| II/0145   | To update sections 4.2, 4.8 and 5.1 of the SmPC in order to add recommendations and data for subsequent and booster doses based on real world evidence (RWE) data as well as interim study results from both sub-study E (SSE) and sub-study D (SSD) C4591031 following procedure II/0140 assessment. The Package Leaflet is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 27/10/2022 | 28/10/2022 | SmPC and PL            | SmPC new text This variation concerns the update of the SmPC to include additional booster doses of Comirnaty in individuals 12 years of age and older at least 3 months between the administration of Comirnaty and the last prior dose of a COVID-19 vaccine. This application is supported with safety and immunogenicity interim results following a fourth booster dose in two subsets from the phase III study C4591031 (substudy D and E). The immune responses after a fourth dose show an increase of the neutralising antibody titres against Wuhan and Omicron BA.1 compared to pre-boost levels. In adults 55 years of age and older, the antibody titre increased 5.8- fold (95% CI: 4.6, 7.2) against Omicron BA.1 strain and |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                  |            |            |                        | 4.3-fold (95% CI: 3.7, 5.0) against Wuhan strain after Comirnaty Original 30Âµg vaccine one month after booster dose. In adults between 18- and 55-years of age, the antibody titres increased 3.4-fold (95% CI: 3.0, 3.8) for Omicron BA.1 and 3.0 (95% CI: 2.7, 3.3) for Wuhan strain. The overall safety profile for the fourth dose was similar to that observed after the Comirnaty booster (third dose). No new safety concerns have been identified. In addition, the MAH presented supportive evidence from observational studies that support an additional booster dose (fourth dose) of Comirnaty to improve protection against COVID-19. Relative vaccine effectiveness (VE) of 34-65% against symptomatic COVID-19 were observed in various studies compared to three doses of the same vaccine. Relative VE against severe infections and hospitalization (64-71%) and death (72-78%) were higher. For more information, please refer to the Summary of   |
|---------|------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0151 | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS | 27/10/2022 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| N/0150  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                 | 27/10/2022 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| X/0138  | Annex I_2.(c) Change or addition of a new strength/potency                                                       | 19/10/2022 | 20/10/2022 | SmPC, Labelling and PL | Please refer to Scientific Discussion 'Comirnaty/H/C/005735/X/0138'                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| R/0137  | Renewal of the marketing authorisation.                                                                          | 15/09/2022 | 10/10/2022 |                        | The CHMP, having reviewed the available information on the status of the fulfilment of the Specific Obligations and having confirmed the positive benefit risk balance of                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

|           |                                                    |            |     | Comirnaty, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated. Furthermore, the CHMP considered that, as all Specific Obligations have been either fulfilled or reclassified as category 3 studies in the RMP, there are no remaining grounds for the marketing authorisation to remain conditional and therefore recommends the granting of a standard marketing authorisation not subject to Specific Obligations for Comirnaty. Please refer to Scientific Discussion 'Comirnaty/H/C/005735/R/0137'   |
|-----------|----------------------------------------------------|------------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0146/G | This was an application for a group of variations. | 29/09/2022 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

|         | processes B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes                                                                                                                                                                                                                                                                       |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0141 | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 15/09/2022 | 16/09/2022 | SmPC and PL | Update of sections 4.4 and 4.8 of the SmPC in order to update the existing information on myocarditis and pericarditis after a third dose and in the age group 5-11 years based on real-world evidence as requested in the outcome of the post Authorization Measure PAM MEA/002.13 (EMEA/H/C/005735/MEA/002.13, dated 08 June 2022). The package leaflet is updated accordingly. In addition, the MAH took the opportunity to implement editorial changes in section 4.4 of the SmPC.                                                                                                                                                                                                                                               |
| II/0129 | Update of sections 4.2, 4.8 and 5.1 of the SmPC of COMIRNATY 10 Î¼g Concentrate for dispersion for injection in order to introduce a booster dose for children 5 to 11 years of age based on interim results from study C4591007; this is a Phase 1, Open-Label Dose-Finding Study to Evaluate Safety, Tolerability, and Immunogenicity and Phase 2/3 Placebo-Controlled, Observer-Blinded Safety, Tolerability, and Immunogenicity Study of a SARS- CoV-2 RNA Vaccine Candidate Against COVID-19 in Healthy Children and Young Adults; the Package Leaflet is updated accordingly. | 15/09/2022 | 16/09/2022 | SmPC and PL | The administration of a third booster dose of Comirnaty in children 5 to 11 years of age is supported by data from clinical study C4591007; this is an-going, randomized, placebo-controlled, Phase 1/2/3 study including healthy children from 6 months to <12 years of age. Efficacy of the booster dose in this age group was inferred by immunogenicity. The immunogenicity was assessed based on: SARS-CoV-2 neutralizing geometric mean titres (GMTs), geometric mean ratio (GMR) and seroresponse. The results from study C4591007 indicated an increase of SARS-CoV-2 neutralizing GMT against the wild-type strain, in children 5 through 11 years of age who had no serological or virological evidence of past SARS-CoV-2 |

<div style=\"page-break-after: always\"></div>

|           | In addition, the MAH took the opportunity to make minor editorial changes throughout the product information. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                   |            |            |                        | infection, from 1253.9, 1-month post-dose 2 (primary series) to 2720.9, 1 month post-dose 3 (booster). This results in a GMR post-dose 3/post-dose 2 of 2.17 (2-sided 95% CI: 1.76, 2.68). The seroresponse rate was almost 100% after the third booster dose, using pre-dose values as reference. This is suggestive of an adequate boosting response. The safety profile after booster dose was consistent with the safety profile known for primary series of Comirnaty administered to children of the same age range. The most frequent adverse reactions were injection site pain, fatigue, headache, myalgia, chills, injection site redness and swelling.   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0143   | B.I.a.6.a - Changes to the active substance of a vaccine against human coronavirus - Replacement or addition of a serotype, strain, antigen or coding sequence or combination of serotypes, strains, antigens or coding sequences for a human coronavirus vaccine | 12/09/2022 | 12/09/2022 | SmPC, Labelling and PL | Addition of a new strain (Omicron BA.4-5) resulting in a new Comirnaty Original/Omicron BA.4-5 (15/15 micrograms)/dose dispersion for injection presentation. The SmPC, the Package Leaflet and Labelling are updated accordingly. A revised RMP version 7.1 has been approved.                                                                                                                                                                                                                                                                                                                                                                                     |
| II/0140   | B.I.a.6.a - Changes to the active substance of a vaccine against human coronavirus - Replacement or addition of a serotype, strain, antigen or coding sequence or combination of serotypes, strains, antigens or coding sequences for a human coronavirus vaccine | 01/09/2022 | 01/09/2022 | SmPC, Labelling and PL | Addition of a new strain (Omicron BA.1) resulting in a new Comirnaty Original/Omicron BA.1 (15 Î¼g tozinameran/ 15 Î¼g riltozinameran)/dose dispersion for injection presentation. The Annex A, the SmPC, the Labelling and the Package Leaflet are updated accordingly. A revised RMP version 6.1 has been approved.                                                                                                                                                                                                                                                                                                                                                 |
| N/0132    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                  | 17/08/2022 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| IB/0142/G | This was an application for a group of variations.                                                                                                                                                                                                                | 01/08/2022 | 05/08/2022 | SmPC                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

|           | B.II.z - Quality change - Finished product - Other variation B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol B.II.f.1.e - Stability of FP - Change to an approved stability protocol                                                                                                                                                                                                            |            |            |             |                                                                                                                                                   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0136   | B.II.f.1.z - Stability of FP - Change in the shelf-life or storage conditions of the finished product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                             | 21/07/2022 | 05/08/2022 | SmPC and PL | The SmPC section 6.1 has been updated as follows: 'Within the 1 month shelf life at 2 Â°C to 8 Â°C, up to 48 hours may be used for transportation.' |
| II/0135/G | This was an application for a group of variations. B.I.a.3.c - Change in batch size (including batch size ranges) of AS or intermediate - The change requires assessment of the comparability of a biological/immunological AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.z - Quality change - Active substance - Other variation B.I.z - Quality change - Active substance - Other variation B.I.z - Quality change - Active substance - Other variation | 21/07/2022 | n/a        |             |                                                                                                                                                   |
| II/0134/G | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 14/07/2022 | n/a        |             |                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

| B.II.e.7.b - Change in components or devices dossier) - Replacement B.II.e.7.b - Change in components or devices dossier) - Replacement B.II.z - Quality change variation B.II.e.7.b - Change in components or devices dossier) - Replacement B.II.b.1.c - Replacement manufacturing site for manufacturing operation(s) release/control, and secondary biol/immunol medicinal forms manufactured by processes B.II.b.2.b - Change to arrangements and quality Replacement/addition control/testing takes place product and any of the biol/immunol method B.II.b.1.a - Replacement manufacturing site for site B.II.b.1.c - Replacement manufacturing site for manufacturing operation(s) release/control, and secondary   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                     | forms manufactured by complex manufacturing processes                                                                                                                                                                                                                                                                                                                                            |            |     |                                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| PSUSA/10898 /202112 | Periodic Safety Update EU Single assessment - tozinameran (COMIRNATY), tozinameran/riltozinameran (COMIRNATY Original/Omicron BA.1), tozinameran/famtozinameran (COMIRNATY Original/Omicron BA.4-5), raxtozinameran (COMIRNATY Omicron XBB.1.5)                                                                                                                                                  | 07/07/2022 | n/a | PRAC Recommendation - maintenance |
| II/0131             | B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method                                                                                                                           | 23/06/2022 | n/a |                                   |
| IAIN/0133/G         | This was an application for a group of variations. B.II.d.1.b - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits for medicinal products subject to OCABR B.II.d.1.b - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits for medicinal products subject to OCABR | 15/06/2022 | n/a |                                   |
| II/0124/G           | This was an application for a group of variations. B.II.f.z - Stability of FP - Other variation                                                                                                                                                                                                                                                                                                  | 10/06/2022 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |            |     |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| II/0130/G | This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a | 02/06/2022 | n/a |

<div style=\"page-break-after: always\"></div>

| B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method B.II.b.4.c - Change in the batch size (including batch size ranges) of the finished product - The change requires assessment of the comparability of a biological/immunological medicinal product or a new bioequivalence study B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.3.b - Change in the manufacturing process of the finished or intermediate product - Substantial changes to a manufacturing process that may have a significant impact on the quality, safety and efficacy of the medicinal product B.II.z - Quality change - Finished product - Other variation B.II.b.3.b - Change in the manufacturing process of the finished or intermediate product - Substantial changes to a manufacturing process that may have a significant impact on the quality, safety and efficacy of the medicinal product B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP -   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

<!-- image -->

| control/testing takes place product and any of the test biol/immunol method B.II.b.2.b - Change to importer, arrangements and quality Replacement/addition of control/testing takes place product and any of the test biol/immunol method B.II.z - Quality change - variation B.II.b.1.c - Replacement manufacturing site for the manufacturing operation(s) release/control, and secondary biol/immunol medicinal forms manufactured by processes B.II.d.2.a - Change in test product - Minor changes procedure B.II.b.2.b - Change to importer, arrangements and quality Replacement/addition of control/testing takes place product and any of the test biol/immunol method B.II.b.1.c - Replacement manufacturing site for the manufacturing operation(s) release/control, and secondary   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|           | manufactured by complex manufacturing processes B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure   |            |     | forms   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|---------|
| IB/0127   | B.II.c.z - Change in control of excipients in the Finished Product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 25/05/2022 | n/a |         |
| IA/0128/G | This was an application for a group of variations. B.II.c.4.a - Change in synthesis or recovery of a non- pharmacopoeial or novel excipient - Minor change B.II.c.4.a - Change in synthesis or recovery of a non- pharmacopoeial or novel excipient - Minor change                                                                                                                                                                                                                                                                                                                                                                                                                                 | 12/05/2022 | n/a |         |
| II/0125/G | This was an application for a group of variations. B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 12/05/2022 | n/a |         |

<div style=\"page-break-after: always\"></div>

|           | change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product B.I.z - Quality change - Active substance - Other variation                                                                                                                                                                                                                                                                    |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| N/0113    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                          | 11/05/2022 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| II/0104   | Update of sections 4.2, 4.8 and 5.1 of the SmPC of Comirnaty 30 microgram/dose and section 4.8 of the SmPC of Comirnaty 10 microgram/dose in order to update immunogenicity, safety and efficacy information regarding heterologous booster vaccination based on published literature data; the Package Leaflet is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 22/04/2022 | 04/05/2022 | SmPC and PL | The immunogenicity, safety and efficacy of an heterologous booster dose of Comirnaty 30 Âµg in individuals 18 years of age and older who have received a primary course comprised of another mRNA vaccine or adenoviral vector vaccine has been assessed. This review took into consideration all available data from clinical studies, post- marketing and real-world evidence. No new safety concerns have been identified. The reviewed literature evidence as well as the recommendations taken for the other mRNA vaccine approved in the EU further supported the shortening of the boosting interval to at least three months after completion of the primary course. |
| II/0126/G | This was an application for a group of variations. B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for                                                                  | 26/04/2022 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

|           | biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |            |     |                   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------|
| IB/0123   | B.I.z - Quality change - Active substance - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 19/04/2022 | n/a |                   |
| II/0120/G | This was an application for a group of variations. B.II.c.z - Change in control of excipients in the Finished Product - Other variation B.II.c.2.a - Change in test procedure for an excipient - Minor changes to an approved test procedure B.II.c.z - Change in control of excipients in the Finished Product - Other variation B.II.c.2.d - Change in test procedure for an excipient - Other changes to a test procedure (including replacement or addition) B.II.c.2.d - Change in test procedure for an excipient - Other changes to a test procedure (including replacement or addition) B.II.c.1.b - Change in the specification parameters and/or limits of an excipient - Addition of a new specification parameter to the specification with its corresponding test method B.II.c.2.d - Change in test procedure for an excipient - Other changes to a test procedure (including replacement or addition) B.II.c.4.a - Change in synthesis or recovery of a non- | 07/04/2022 | n/a | pharmacopoeial or |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| IB/0122   | B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 04/04/2022   | 07/04/2022   | SmPC and PL   | Update of the product information to extend the shelf life of COMIRNATY 30 Âµg Concentrate for dispersion for injection (EU/1/20/1528/001) from 9 to 12 months.   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|---------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0116/G | This was an application for a group of variations. B.I.z - Quality change - Active substance - Other variation B.I.z - Quality change - Active substance - Other variation B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test method at the site is a biol/immunol method B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting | 31/03/2022   | 07/04/2022   | Annex II      |                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

| IB/0106/G   | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 31/03/2022   | n/a   |                                 |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|---------------------------------|
| II/0112/G   | This was an application for a group of variations. B.II.b.3.b - Change in the manufacturing process of the finished or intermediate product - Substantial changes to a manufacturing process that may have a significant impact on the quality, safety and efficacy of the medicinal product B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.4.c - Change in the batch size (including batch size ranges) of the finished product - The change requires assessment of the comparability of a biological/immunological medicinal product or a new bioequivalence study B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch | 24/03/2022   | n/a   | control/testing takes place for |

<div style=\"page-break-after: always\"></div>

|           | and any of the test methods at the site is a method                                                                                                                                                                                                                                                                                                                                                                 |            |            |             | product biol/immunol           |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------|
| II/0105   | B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product                                                                                                                                                                                 | 24/03/2022 | n/a        |             |                                |
| II/0121/G | application for a group of variations. B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol B.II.f.1.c - Stability of FP - Change in storage conditions for biological medicinal products, when the stability studies have not been performed in approved stability protocol         | 23/03/2022 | 07/04/2022 | SmPC and PL | This was an accordance with an |
| IB/0119/G | This was an application for a group of variations. B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished variation | 22/03/2022 | n/a        |             | product - Other                |

<div style=\"page-break-after: always\"></div>

| II/0109/G   | This was an application for a group of variations.                                                                                                                                                                                                                                              | 10/03/2022   | n/a   |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|
| II/0087     | C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required  | 10/03/2022   | n/a   |
| II/0115/G   | This was an application for a group of variations. B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical | 03/03/2022   | n/a   |

<div style=\"page-break-after: always\"></div>

| forms manufactured by processes B.II.b.1.c - Replacement manufacturing site for manufacturing operation(s) release/control, and secondary biol/immunol medicinal forms manufactured by processes B.II.b.1.c - Replacement manufacturing site for manufacturing operation(s) release/control, and secondary biol/immunol medicinal forms manufactured by processes B.II.b.1.c - Replacement manufacturing site for manufacturing operation(s) release/control, and secondary biol/immunol medicinal forms manufactured by processes B.II.b.4.b - Change in the size ranges) of the finished down to 10-fold B.II.b.3.a - Change in the the finished or intermediate in the manufacturing process B.II.e.7.b - Change in supplier components or devices   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|           | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method   |            |            |             |                                                                                                                                                                                                                      |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0114   | B.I.b.1.a - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits for medicinal products subject to OCABR                                                                                                                                                                                                                | 03/03/2022 | n/a        |             |                                                                                                                                                                                                                      |
| IB/0117/G | This was an application for a group of variations. B.III.2.z - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Other variation A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                | 02/03/2022 | n/a        |             |                                                                                                                                                                                                                      |
| II/0111   | Update of section 4.2 of the SmPC of Comirnaty 30 microgram/dose to lower the age of the booster dose from adults 18 years of age and older to adults and adolescents 12 years of age and older, based on real world evidence collected by the Ministry of Health of Israel. The Package Leaflet is updated accordingly.                                                                                      | 24/02/2022 | 28/02/2022 | SmPC and PL | SmPC new text A booster dose of Comirnaty may be administered intramuscularly at least 6 months after the second dose in individuals 12 years of age and older. For more information, please refer to the Summary of |

<div style=\"page-break-after: always\"></div>

|           | In addition, the MAH took the opportunity to make minor editorial changes throughout the product information (SmPC and package leaflet). C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |            |            |                        | Product Characteristics.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0093   | Update of sections 4.2, 4.4, 4.8 and 5.1 of the SmPC of Comirnaty 30 microgram/dose and section 4.8 of the SmPC of Comirnaty 10 microgram/dose in order to update efficacy and safety information after booster dose and change posology recommendations for booster use from \"individuals 18 years of age and older\" to \"individuals 16 years of age and older\", based on interim results from study C4591031, this is a randomized, placebo-controlled, phase 3 booster efficacy study involving participants â¥ 16 years of age who completed the primary series of BNT162b2 30 Î¼g in Study C4591001, published literature data and post-marketing safety data. The Package Leaflet and Labelling are updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 24/02/2022 | 28/02/2022 | SmPC, Labelling and PL | SmPC new text A booster dose of Comirnaty may be administered intramuscularly at least 6 months after the second dose in individuals 16 years of age and older. The relative vaccine efficacy information for participants 16 years of age and older without prior evidence of SARS-CoV- 2 infection was 95.3% (95% confidence interval of 89.5% to 98.3%). Relative vaccine efficacy in participants with or without evidence of prior SARS-CoV-2 infection was 94.6% (95% confidence interval of 88.5% to 97.9%), similar to that seen in those participants without evidence of prior infection. The overall safety profile for the booster dose was similar to that seen after 2 doses. For more information, please refer to the Summary of Product Characteristics. |
| II/0056/G | This was an application for a group of variations. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 17/02/2022 | 28/02/2022 | Annex II               | To address specific obligations on quality, the MA Holder provided relevant data and proposed changes to the dossier, in line with the requirements and due dates set by CHMP. With regards to SO1, the MA Holder has provided additional                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required B.I.b.1.a - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits for medicinal products subject to OCABR B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.II.d.1.b - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits for medicinal products subject to OCABR B.II.d.1.b - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits for medicinal products subject to OCABR B.II.d.1.b - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits for medicinal products subject to OCABR B.II.d.1.b - Change in the specification parameters   | characterisation data as requested. a) The potential for truncated transcripts to produce proteins/peptides was further investigated using a cell-free in vitro expression system. No truncated or other protein species were detected beyond the background bands observed in the negative control sample. The MAH will complement the characterization exercise using the cell- free in vitro translation system with additional tozinameran batches. b) It is sufficiently demonstrated that the major proportion of fragmented species contains the 5'-cap but lacks the poly(A) tail. c) WB results obtained by three different antibodies, specific for the S1 domain, the receptor binding domain and the S2 domain, respectively, were presented and compared to theoretical masses of the S-protein and the subdomains in glycosylated and non-glycosylated forms. It is sufficiently justified that the major band monitored corresponds to the heavily glycosylated S-protein. With regards to SO2, the MA Holder provided additional information to enhance the control strategy, including the active substance and finished product specifications. a) For active substance the acceptance criterion for 5'- Cap has been tightened. For finished product acceptance criteria for osmolality, LNP size, RNA encapsulation, RNA content and lipids content (ALC-0315, ALC-0159, DSPC, cholesterol) and in vitro expression (IVE) assay have been tightened. The revised limits are sufficiently justified and found acceptable. The acceptance criteria for RNA integrity test in active substance and finished product specifications have been previously tightened during VAR IB-31-G. b) A new test method has been introduced and   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         | and/or limits of the finished product - Tightening of specification limits for medicinal products subject to OCABR B.II.d.1.b - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits for medicinal products subject to OCABR B.II.d.1.b - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits for medicinal products subject to OCABR B.II.d.1.b - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits for medicinal products subject to OCABR B.II.d.1.b - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits for medicinal products subject to OCABR B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol B.I.z - Quality change - Active substance - Other variation   |            |            |             | acceptably validated. c) The MAH previously presented data supporting the suitability of the ddPCR method, as being capable of detecting changes in the poly(A) tail content. The accuracy of the ddPCR method is sufficiently addressed. d) The acceptance criteria for RNA integrity test in active substance and finished product specifications have been previously tightened during VAR IB-31-G. The justifications for no further tightening of the finished product specifications for RNA integrity and LNP polydispersity in the current variation have been acceptably justified. e) Additional details have been provided to support the suitability of the IVE assay (cell-based flow cytometry) used for potency determination. f) Evaluation of lipid-related impurities in the finished product and discussion on ALC-0315 impact on late migrating species (LMS) and RNA integrity were provided and assessed via parallel VAR II-54-G. Based on the provided information, SO1 and SO2 are considered fulfilled. The provided data also fulfils recommendations on analytical methods (REC 10) and additional stability (REC 20). The Annex IIE has been updated as follows: â¢ SO1 (relating to characterisation of the active substance and finished product) is deleted from the list of specific obligations. â¢ SO2 (relating to control strategy, including the active substance and finished product specifications) is   |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0110 | C.I.z - Changes (Safety/Efficacy) of Human and                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 15/02/2022 | 28/02/2022 | SmPC and PL | To update section 4.6 of the SmPC and section 2 of the PL                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

|           | Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |            |     | to implement the recommendation on vaccination with Comirnaty in pregnant and breastfeeding women as requested by the CHMP.   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------------------------------------------------------------------------------------------------------------------|
| II/0108/G | This was an application for a group of variations. B.II.c.2.a - Change in test procedure for an excipient - Minor changes to an approved test procedure B.II.c.z - Change in control of excipients in the Finished Product - Other variation B.II.c.2.z - Change in test procedure for an excipient - Other variation B.II.c.1.b - Change in the specification parameters and/or limits of an excipient - Addition of a new specification parameter to the specification with its corresponding test method B.II.c.2.d - Change in test procedure for an excipient - Other changes to a test procedure (including replacement or addition) B.II.c.2.d - Change in test procedure for an excipient - Other changes to a test procedure (including replacement or addition) B.II.c.2.d - Change in test procedure for an excipient - Other changes to a test procedure (including replacement or addition) B.II.c.4.a - Change in synthesis or recovery of a non- pharmacopoeial or novel excipient - Minor change B.II.c.z - Change in control of excipients in the Finished Product - Other variation | 10/02/2022 | n/a |                                                                                                                               |
| IB/0107/G | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 07/02/2022 | n/a |                                                                                                                               |

<div style=\"page-break-after: always\"></div>

|           | B.II.c.2.d - Change in test procedure for an excipient - Other changes to a test procedure (including replacement or addition) B.II.c.z - Change in control of excipients in the Finished Product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                              |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0102   | Update of sections 4.8 and 5.1 of the SmPC in order to update safety and efficacy information 6 months post-dose 2 follow-up for adolescence 12 through 15 years of age based on updated interim results from study C4591001, listed as a specific obligation; this is a Phase 1/2/3, placebo-controlled, observer-blind, interventional, dose-finding, study to evaluate the safety, tolerability, immunogenicity and efficacy of SARS-CoV-2 RNA vaccine candidates against COVID- 19 in healthy individuals. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 27/01/2022 | 04/02/2022 | SmPC and PL | Updated efficacy analyses were performed with additional confirmed COVID-19 cases accrued during blinded placebo- controlled follow-up, representing up to 6 months after Dose 2 in the efficacy population. In the updated efficacy analysis of Study 2 in adolescents 12 to 15 years of age without evidence of prior infection, there were no cases in 1,057 participants who received the vaccine and 28 cases out of 1,030 who received placebo. The point estimate for efficacy is 100% (95% confidence interval 86.8, 100.0). In participants with or without evidence of prior infection there were 0 cases in the 1,119 who received vaccine and 30 cases in 1,109 participants who received placebo. This also indicates the point estimate for efficacy is 100% (95% confidence interval 87.5, 100.0). For more information, please refer to the Summary of Product Characteristics. |
| II/0092/G | This was an application for a group of variations. B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method B.I.a.1.j - Change in the manufacturer of AS or of a                                                                                                                                                                                                                                                   | 03/02/2022 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

|         | starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test method at the site is a biol/immunol method                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |            |            |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0090 | B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 27/01/2022 | n/a        |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| IB/0100 | B.II.c.z - Change in control of excipients in the Finished Product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 24/01/2022 | n/a        |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| II/0080 | Update of section 4.4 of the SmPC in order to amend an existing warning on anxiety-related reactions to add hypoaesthesia and paraesthesia and remove tingling sensations following the outcome of the Post-Authorisation Measure MEA-002.8 (EMEA/H/C/005735/MEA/002.8, dated 30 September 2021). Update of section 4.8 of the SmPC in order to add hypoaesthesia and paraesthesia to the list of adverse drug reactions (ADRs) with frequency 'not known' following the outcome of the Post-Authorisation Measure MEA-002.8 (EMEA/H/C/005735/MEA/002.8, dated 30 September 2021). The Package Leaflet is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 13/01/2022 | 24/01/2022 | SmPC | Following the assessment of clinical trial, literature and post-marketing safety data, a total of 21,793 cases were identified of which approximately 75% occurred within the day after vaccination. When available (~15% of the cases), the duration of the event was reported to be â¤2 days in ~70% of the cases, which is considered a plausible time to onset (TTO). Hypoesthesia and paraesthesia are not sufficiently covered in the product information by the currently included text regarding stress-related reactions. Although approximately 60% of the cases co-reported symptoms associated with an acute stress response/vasovagal episode, the remaining cases were not observed in the context of stress-related reactions (n = 9446). In these cases, co-reported events included reactogenicity adverse drug reactions (ADRs) listed in the product information. Thus, the existing warning on anxiety-related reactions in the SmPC section 4.4 has been amended to remove tingling |

<div style=\"page-break-after: always\"></div>

|                     |                                                                                                                                                                                                                                                                                                                                                                                                                           |            |            |             | sensations and add paraesthesia and hypoaesthesia. These ADRs (paraesthesia and hypoaesthesia) have also been added to the list of adverse drug reactions with frequency 'not known' in the SmPC section 4.8.                                                             |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0101             | B.II.f.1.c - Stability of FP - Change in storage conditions for biological medicinal products, when the stability studies have not been performed in accordance with an approved stability protocol                                                                                                                                                                                                                       | 21/01/2022 | 04/02/2022 | SmPC and PL | The SmPC section 6.3 of the 30 micrograms/dose and 10 micrograms/dose Tris-sucrose formulations (EU/1/20/1528/002-005) has been updated to remove the possibility of distribution at -25Â°C to -15Â°C. Distribution is performed under frozen conditions at -90Â°C to -60Â°C. |
| II/0075/G           | This was an application for a group of variations. B.II.d.2.c - Change in test procedure for the finished product - Substantial change to or replacement of a biol/immunol/immunochemical test method or a method using a biol. reagent or replacement of a biol. reference preparation not covered by an approved protocol B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor | 13/01/2022 | n/a        |             |                                                                                                                                                                                                                                                                           |
| PSUSA/10898 /202106 | Periodic Safety Update EU Single assessment - tozinameran (COMIRNATY), tozinameran/riltozinameran (COMIRNATY Original/Omicron BA.1), tozinameran/famtozinameran (COMIRNATY Original/Omicron BA.4-5), raxtozinameran (COMIRNATY Omicron XBB.1.5)                                                                                                                                                                           | 13/01/2022 | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                         |
| IA/0103             | B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the                                                                                                                                                                                                                                                                                                                                 | 10/01/2022 | n/a        |             |                                                                                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

|           | dossier) - Replacement or addition of a supplier                                                                                                                                                                                                                                                                                  |            |     |                              |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------------------------|
| IB/0099/G | This was an application for a group of variations. B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation B.II.b.3.z - Change in the manufacturing process of product - Other variation                                                                       | 10/01/2022 | n/a | the finished or intermediate |
| IB/0098   | B.I.c.1.z - Change in immediate packaging of the AS - Other variation                                                                                                                                                                                                                                                             | 10/01/2022 | n/a |                              |
|           | This was an application for a group of variations. B.II.c.z - Change in control of excipients in the Finished Product - Other variation B.II.c.4.a - Change in synthesis or recovery of a non- pharmacopoeial or novel excipient - Minor change B.II.c.2.a - Change in test procedure for an excipient an approved test procedure | 04/01/2022 | n/a | IB/0096/G - Minor changes to |
| II/0097   | B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes                                | 21/12/2021 | n/a |                              |
| II/0089   | B.I.a.3.c - Change in batch size (including batch size ranges) of AS or intermediate - The change requires                                                                                                                                                                                                                        | 16/12/2021 | n/a |                              |

<div style=\"page-break-after: always\"></div>

|           | assessment of the comparability of a biological/immunological AS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |            |            |          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0054/G | This was an application for a group of variations. B.II.z - Quality change - Finished product - Other variation A.7 - Administrative change - Deletion of manufacturing sites B.II.c.2.a - Change in test procedure for an excipient - Minor changes to an approved test procedure B.II.c.2.a - Change in test procedure for an excipient - Minor changes to an approved test procedure B.II.c.2.a - Change in test procedure for an excipient - Minor changes to an approved test procedure B.II.c.2.a - Change in test procedure for an excipient - Minor changes to an approved test procedure B.II.c.z - Change in control of excipients in the Finished Product - Other variation B.II.c.z - Change in control of excipients in the Finished Product - Other variation B.II.c.1.b - Change in the specification parameters and/or limits of an excipient - Addition of a new specification parameter to the specification with its corresponding test method B.II.c.1.a - Change in the specification parameters and/or limits of an excipient - Tightening of specification limits B.II.c.1.b - Change in the specification parameters and/or limits of an excipient - Addition of a new | 16/12/2021 | 24/01/2022 | Annex II | To address specific obligations SO4 and SO5, a reassessment of the ALC-0315 and ALC-0159 lipid control strategies was performed including impurity understanding and control, specifications for starting materials, intermediates, and the final ALC-0315 and ALC-0159 lipids and supporting data for method validation and stability data were provided. Evaluation of lipid-related impurities in the drug product and discussion on ALC-0315 impact on late migrating species (LMS) and RNA integrity were provided in the response to SO2 (f). Based on the provided information, SO2 (f), SO4 and SO5 are considered fulfilled. The Annex IIE has been updated as follows: â¢ SO4 relating to excipient ALC-0315 is deleted from the list of specific obligations. â¢ SO5 relating to excipient ALC-0159 is deleted from the list of specific obligations. |

<div style=\"page-break-after: always\"></div>

|           | B.II.c.1.a - Change in the specification parameters and/or limits of an excipient - Tightening of specification limits C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required                |            |            |             |                                                                                                                                                                                                                                  |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0094/G | This was an application for a group of variations. B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change | 13/12/2021 | n/a        |             |                                                                                                                                                                                                                                  |
| IB/0091   | B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol                                                                                                                                                                                                                                                  | 09/12/2021 | 09/12/2021 | SmPC and PL | Update of Product Information to extend the shelf life from 6 to 9 months.                                                                                                                                                       |
| IAIN/0095 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                       | 07/12/2021 | 07/12/2021 | SmPC and PL | To update sections 4.4 and 4.8 of the SmPC and sections 2 and 4 of the PL to implement the signal recommendations on 'Signal assessment report on Myocarditis, pericarditis with Tozinameran (COVID-19 mRNA vaccine (nucleoside- |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |            |            |                        | modified) - COMIRNATY)   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|--------------------------|
| II/0086   | B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product                                                                                                                                                                                                                             | 26/11/2021 | n/a        |                        |                          |
| X/0077    | Annex I_2.(c) Change or addition of a new strength/potency                                                                                                                                                                                                                                                                                                                                                                                                      | 25/11/2021 | 26/11/2021 | SmPC, Labelling and PL |                          |
| IB/0088/G | This was an application for a group of variations. B.II.b.4.f - Change in the batch size (including batch size ranges) of the finished product - The scale for a biological/immunological medicinal product is increased/decreased without process change (e.g. duplication of line) B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place | 23/11/2021 | n/a        |                        |                          |
| IB/0085/G | This was an application for a group of variations. B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.4.f - Change in the batch size (including batch size ranges) of the finished product - The scale for a biological/immunological medicinal product is increased/decreased without process change (e.g.                                                            | 19/11/2021 | n/a        |                        |                          |

<div style=\"page-break-after: always\"></div>

|           | duplication of line) B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |            |     |           |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------|
| IB/0084/G | This was an application for a group of variations. B.II.z - Quality change - Finished product - Other variation B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished Addition of a new test(s) and limits | 19/11/2021 | n/a | product - |
| II/0083/G | This was an application for a group of variations. B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 17/11/2021 | n/a |           |

<div style=\"page-break-after: always\"></div>

|           | manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes                                                                                                                                                                                                                                                                                                                                      |            |            |                        |                                                                                                                          |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|--------------------------------------------------------------------------------------------------------------------------|
| IAIN/0082 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 16/11/2021 | 18/11/2021 | SmPC and PL            | To update section 4.8 of the SmPC and section 4 of the PL to implement the signal recommendation on erythema multiforme. |
| IB/0081   | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                                                                                                                                                                                                                                                                                                                           | 08/11/2021 | n/a        |                        |                                                                                                                          |
| N/0079    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                               | 03/11/2021 | 18/11/2021 | PL                     | To update section 2 of the PL regarding the wording on immunity of the third dose.                                       |
| R/0046    | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 14/10/2021 | 03/11/2021 |                        | Please refer to Scientific Discussion 'EMEA/H/C/005735/R/0046`                                                           |
| X/0044/G  | This was an application for a group of variations. Extension application to add new pharmaceutical form (dispersion for injection) with a new strength (0.1mg/ml). Update sections 6.4, 6.5 and 6.6 of the SmPC, section 5, 6 and information for healthcare professionals of the PL, section 1 of the Carton Box Label as well as section 1 and 5 of the Vial Label to ensure the correct handling by providing dose verification information about strength, age range, colour information of the flip-off plastic cap and greyscale images. | 14/10/2021 | 03/11/2021 | SmPC, Labelling and PL | Please refer to Scientific Discussion 'EMEA/H/C/005735/X/0044`                                                           |

<div style=\"page-break-after: always\"></div>

|           | Update sections 4.2 of the SmPC ensure the correct handling in accordance to interchangeability of the medicinal product. Update section 8 of Carton Box Label to clarify expiry date 'EXP' by adding storage temperature '(at -90Â°C to -60Â°C)' to ensure the correct handling of the medicinal product. Change the name of the active substance from COVID-19 mRNA Vaccine (nucleoside modified) to Tozinameran. Annex I_2.(c) Change or addition of a new strength/potency Annex I_2.(d) Change or addition of a new pharmaceutical form C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation A.3 - Administrative change - Change in name of the   |            |     |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| II/0078/G | This was an application for a group of variations. B.II.z - Quality change - Finished product - Other variation B.II.e.4.b - Change in shape or dimensions of the container or closure (immediate packaging) - The change in shape or dimensions concerns a fundamental part, which may have a significant                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 29/10/2021 | n/a |

<div style=\"page-break-after: always\"></div>

|           | impact on the delivery, use, safety or stability of the FP                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |            |                        |                                                                                                                                                                                                                              |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0069/G | This was an application for a group of variations. Grouped variation: Type II, B.II.a.3.b.3, Changes in the composition of the finished product to add sodium hydroxide and hydrochloric acid as pH adjustment excipients (present in the purchased 1500 mM PBS buffer, pH 6.81). Type IB, B.II.b.3.a, Minor changes in the manufacturing process of the finished product to introduce the use of an in-line dilution skid to prepare 50 mM citrate and 150 mM PBS buffers. B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.a.3.b.3 - Changes in the composition (excipients) of the finished product - Other excipients - Change that relates to a biological/immunological | 28/10/2021 | 18/11/2021 | SmPC, Labelling and PL | The SmPC section 6.1 (EU/1/20/1528/001) has been updated to include the following excipients: Sodium hydroxide (for pH-adjustment) Hydrochloric acid (for pH-adjustment) The Labelling and PL have been updated accordingly. |
| IB/0076   | B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 18/10/2021 | n/a        |                        |                                                                                                                                                                                                                              |
| IB/0074/G | This was an application for a group of variations. B.II.c.z - Change in control of excipients in the Finished Product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 18/10/2021 | n/a        |                        |                                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

|           | - Change in test procedure for an excipient Other changes to a test procedure (including or addition)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |            |     | B.II.c.2.d - replacement   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------------------------|
| N/0051    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 14/10/2021 | n/a |                            |
| II/0072/G | This was an application for a group of variations. B.II.c.z - Change in control of excipients in the Finished Product - Other variation B.II.c.4.a - Change in synthesis or recovery of a non- pharmacopoeial or novel excipient - Minor change B.II.z - Quality change - Finished product - Other                                                                                                                                                                                                                                                                                                                                                       | 11/10/2021 | n/a | variation                  |
| II/0073/G | This was an application for a group of variations. B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes | 07/10/2021 | n/a |                            |

<div style=\"page-break-after: always\"></div>

|           | B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier   |            |     |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| II/0071   | B.II.b.3.c - Change in the manufacturing process of the finished or intermediate product - The product is a biological/immunological medicinal product and the change requires an assessment of comparability                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 06/10/2021 | n/a |
| IB/0068/G | This was an application for a group of variations. B.II.f.1.e - Stability of FP - Change to an approved stability protocol B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new test(s) and limits B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new test(s) and limits B.II.b.5.b - Change to in-process tests or limits                                                                                                                                                                                      | 04/10/2021 | n/a |

<div style=\"page-break-after: always\"></div>

|         | applied during the manufacture of the finished product - Addition of a new test(s) and limits B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product                                                                                                                                                                                                                                                                 |            |            |             |                                                                 |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------------------------------------|
| II/0067 | Update of sections 4.2, 4.4, 4.8 and 5.1 of the SmPC in order to introduce a booster dose (third dose) of Comirnaty for individuals 18 years of age and older, based on interim safety and immunogenicity data from the interventional study C4591001, ' A Phase 1/2/3, placebo-controlled, randomized, observer- blind, dose-finding study to evaluate the safety, tolerability, immunogenicity, and efficacy of SARS- CoV-2 RNA vaccine candidates against COVID-19 in healthy individuals'. The package leaflet is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance | 04/10/2021 | 05/10/2021 | SmPC and PL | Please refer to Scientific Discussion 'EMEA/H/C/005735/II/0067` |
| II/0062 | Update of sections 4.2 and 4.4 of the SmPC in order to introduce a third dose of Comirnaty for individuals 12 years of age and older who are severely immunocompromised, based on published literature data; the Package Leaflet is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to                                                                                                                                                                                                                                                                                                                                           | 04/10/2021 | 05/10/2021 | SmPC and PL | Please refer to Scientific Discussion 'EMEA/H/C/005735/II/0062` |

<div style=\"page-break-after: always\"></div>

|         | new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                   |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0059 | C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required | 30/09/2021 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| IB/0070 | B.I.b.z - Change in control of the AS - Other variation                                                                                                                                                                                                                                        | 24/09/2021 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| II/0036 | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                            | 16/09/2021 | 23/09/2021 | SmPC and PL | This type II variation updates the product information with updated data (March 2021) from the pivotal study C4591001 with the MAH having conducted an interim analysis containing immunogenicity, efficacy and safety data. The presented efficacy data support the previous conclusions in the initial marketing authorisation approval, and all provided subgroup analyses are in agreement with previous data. A slightly lower point estimate of efficacy (92%) compared to previous analyses was obtained (95%). In addition, the reported interim data in this interim analysis, including reactogenicity and reported adverse events, supports the safety profile of Comirnaty 30Âµg in subjects â¥16 years of age obtained at the initial authorisation. Based on the safety data provided in this interim analysis, hyperhidrosis, night sweats, decreased appetite, asthenia and lethargy was added with a frequency uncommon to the list of adverse reactions in section 4.8 of the SmPC. |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |            |            |             | For more information, please refer to the Summary of Product Characteristics.                                   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------------------------------------------------------------------------------------|
| II/0047/G | This was an application for a group of variations. B.II.c.1.b - Change in the specification parameters and/or limits of an excipient - Addition of a new specification parameter to the specification with its corresponding test method B.II.b.5.d - Change to in-process tests or limits applied during the manufacture of the finished product - Deletion of an in-process test which may have a significant effect on the overall quality of the finished product B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change | 16/09/2021 | n/a        |             |                                                                                                                 |
| II/0066   | B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 13/09/2021 | n/a        |             |                                                                                                                 |
| IB/0061   | B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 10/09/2021 | 23/09/2021 | SmPC and PL | - Update section 6.3 of the SmPC to change the shelf life from 6 months to 9 months when stored at the intended |

<div style=\"page-break-after: always\"></div>

|           | medicinal product in accordance with an approved stability protocol                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |            |     | storage conditions of -90 to -60 Â°C - implement Annex IV according to revised CHMP Opinion dated 22 July 2021 for procedure EMEA/H/C/005735/II/0030 - amend a mistake in section 4 of the PIL as requested in procedure PAM-MEA-002.6 to indicate that swelling of the face may occur in patients who have had facial dermatological fillers instead of facial cosmetic injections - amend section 4.4 of the SmPC for French and Latvian translations according to the agreed wording with the respective national authorities   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0065/G | This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes | 09/09/2021 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| II/0057   | B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 09/09/2021 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

|           | material [-] used in the manufacture of a biological/immunological product                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |     |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| II/0063/G | This was an application for a group of variations. B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place | 02/09/2021 | n/a |

<div style=\"page-break-after: always\"></div>

| II/0052/G   | This was an application for a group of variations. B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test method at the site is a biol/immunol method                                                                                                                                                               | 02/09/2021   | n/a   |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|
| II/0040/G   | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.II.d.2.c - Change in test procedure for the finished product - Substantial change to or replacement of a biol/immunol/immunochemical test method or a method using a biol. reagent or replacement of a biol. reference preparation not covered by an approved protocol B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS | 02/09/2021   | n/a   |

<div style=\"page-break-after: always\"></div>

| II/0053/G   | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.II.c.1.b - Change in the specification parameters and/or limits of an excipient - Addition of a new specification parameter to the specification with its corresponding test method B.II.c.2.d - Change in test procedure for an excipient - Other changes to a test procedure (including replacement or addition) B.II.c.4.a - Change in synthesis or recovery of a non- pharmacopoeial or novel excipient - Minor change B.II.c.z - Change in control of excipients in the Finished Product - Other variation B.II.c.z - Change in control of excipients in the   | 25/08/2021   | n/a   |                              |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|------------------------------|
| II/0060/G   | This was an application for a group of variations. B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.II.b.3.z - Change in the manufacturing process of product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                            | 20/08/2021   | n/a   | the finished or intermediate |

<div style=\"page-break-after: always\"></div>

| B.II.e.7.b - Change components or devices dossier) - Replacement B.II.e.7.b - Change components or devices dossier) - Replacement B.II.e.6.b - Change packaging material not product formulation the product information B.II.e.7.b - Change components or devices dossier) - Replacement B.II.e.7.b - Change components or devices dossier) - Replacement B.II.e.7.b - Change components or devices dossier) - Replacement B.II.e.7.b - Change components or devices dossier) - Replacement B.II.e.6.b - Change packaging material not product formulation the product information B.II.e.7.b - Change components or devices dossier) - Replacement B.II.g.5.c - Implementation an approved change   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|           | B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier   |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0058   | B.I.a.3.e - Change in batch size (including batch size ranges) of AS or intermediate - The scale for a biological/immunological AS is increased/decreased without process change (e.g. duplication of line)                                                                                                                                                                       | 17/08/2021 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| IB/0055   | B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method                                                                                                                                                             | 17/08/2021 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| II/0038/G | This was an application for a group of variations. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                | 22/07/2021 | 23/07/2021 | SmPC and PL | Based on signal detection and evaluation activity in the post-authorisation setting, the section in 4.4 of the SmPC is updated by adding 'vaccine stress-related responses' to the already existing warning on anxiety-related reactions (i.e. including examples on stress-related reactions that may occur in association with the vaccination). The provided data support that these anticipated reactions occur related to vaccination. In addition, as agreed by the PRAC, the product information is also updated to add 'extensive swelling of the vaccinated limb' and 'facial swelling', both at frequency unknown, to the list of adverse drug reactions in |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |            |     | the section 4.8 of the SmPC. The Package Leaflet is updated accordingly. For more information, please refer to the Summary of Product Characteristics.   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0049/G | This was an application for a group of variations. B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch                                                                                                                  | 20/07/2021 | n/a |                                                                                                                                                          |
| II/0041/G | This was an application for a group of variations. B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test method at the site is a biol/immunol method B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product B.I.a.2.a - Changes in the manufacturing process of | 15/07/2021 | n/a |                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

|           | of the AS B.I.e.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product                                                                                                                                                                                                                                                                     |            |            |             |                                                                                                                                                                                                                                                                                                                           |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0048/G | This was an application for a group of variations. B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.4.f - Change in the batch size (including batch size ranges) of the finished product - The scale for a biological/immunological medicinal product is increased/decreased without process change (e.g. duplication of line) | 13/07/2021 | n/a        |             |                                                                                                                                                                                                                                                                                                                           |
| IAIN/0050 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                             | 12/07/2021 | 13/07/2021 | SmPC and PL | To update sections 4.4 and 4.8 of the SmPC and sections 2 and 4 of the PL to implement the signal recommendations from the PRAC Updated Signal assessment report on Myocarditis, Pericarditis with Tozinameran (COVID-19 mRNA vaccine (nucleoside-modified) - COMIRNATY) (EPITT no 19712) adopted by PRAC on 08 July 2021 |
| II/0045/G | This was an application for a group of variations. B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS                                                                                                                       | 09/07/2021 | n/a        |             |                                                                                                                                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

|         | starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test method at the site is a biol/immunol method B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.II.d.2.c - Change in test procedure for the finished product - Substantial change to or replacement of a biol/immunol/immunochemical test method or a method using a biol. reagent or replacement of a biol. reference preparation not covered by an approved protocol B.II.b.2.c.3 - Change to importer, batch release arrangements and quality control testing of the FP - Including batch control/testing for a biol/immunol product and any of the test methods is a biol/immunol/immunochemical method B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a   |            |     |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| II/0043 | B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 07/07/2021 | n/a |

<div style=\"page-break-after: always\"></div>

| IB/0042/G   | This was an application for a group of variations.   | 18/06/2021   | n/a   | B.II.e.4.c container medicinal B.II.g.5.c   |
|-------------|------------------------------------------------------|--------------|-------|---------------------------------------------|

<div style=\"page-break-after: always\"></div>

|           | - Deletion of a supplier - Implementation of changes foreseen in approved change management protocol - For a medicinal product                                                                                                                                                                                                                                                                                                                                                                                                    |            |     | dossier) B.II.g.5.c an biological/immunological   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|---------------------------------------------------|
| II/0039/G | This was an application for a group of variations. B.II.c.1.b - Change in the specification parameters and/or limits of an excipient - Addition of a new specification parameter to the specification with its corresponding test method B.II.c.2.d - Change in test procedure for an excipient - Other changes to a test procedure (including replacement or addition) B.II.c.4.a - Change in synthesis or recovery of a non- pharmacopoeial or novel excipient - Minor change B.II.c.z - Change in control of excipients in the | 08/06/2021 | n/a | Finished Product - Other                          |
| II/0035/G | This was an application for a group of variations. B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch and secondary packaging, for   | 01/06/2021 | n/a | release/control,                                  |

<div style=\"page-break-after: always\"></div>

|         | biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.z - Quality change - Finished product - Other variation   |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0030 | Extension of the existing indication from \"individuals 16 years of age and older\" to \"individuals 12 years of age and older\" for Comirnaty; as a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 2.0 of the RMP has also been submitted. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one                        | 28/05/2021 | 31/05/2021 | SmPC and PL | The application for extension of the indication to include adolescents 12-15 years of age is based on a single pivotal phase 1/2/3 study C4591001. It is an extension of the pivotal efficacy study in adults assessed in the initial approval of Comirnaty. The inferential analysis for the 12- 15 year olds which was to demonstrate non-inferior immune responses in this age cohort, compared to subjects 16-25 years from the initial efficacy part of the same study. The effects of Comirnaty in children were investigated in 2,260 children aged 12 to 15 years. The trial showed that the immune response to Comirnaty in this group was comparable to the immune response in the 16 to 25 age group. The efficacy of Comirnaty was calculated in close to 2,000 children from 12 to 15 years of age who had no sign of previous infection. These received either the vaccine or a placebo. Of the 1,005 children receiving the vaccine, none developed COVID-19 compared to 16 children out of the 978 who received the placebo. This means that, in this study, the vaccine was 100% effective at preventing |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                                                          |            |     | COVID-19 (although the true rate could be between 75% and 100%). The most common side effects in children aged 12 to 15 are similar to those in people aged 16 and above. They include pain at the injection site, tiredness, headache, muscle and joint pain, chills and fever. These effects are usually mild or moderate and improve within a few days from the vaccination. The CHMP concluded that the benefits of Comirnaty in this age group outweigh the risks. The CHMP also noted that due to the limited number of children included in the study, the trial could not have detected rare side effects. The committee also noted that EMA's safety committee PRAC is currently assessing very rare cases of myocarditis and pericarditis that occurred after vaccination with Comirnaty, mainly in people under 30 years of age. Currently there is no indication that these cases are due to the vaccine and EMA is closely monitoring this issue. Despite this uncertainty, the CHMP considered that benefits of Comirnaty in children aged 12 to 15 outweigh the risks, in particular in children with conditions that increase the   |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0034 | B.II.d.2.c - Change in test procedure for the finished product - Substantial change to or replacement of a biol/immunol/immunochemical test method or a method using a biol. reagent or replacement of a biol. reference preparation not covered by an approved protocol | 28/05/2021 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| IB/0037 | B.II.c.2.d - Change in test procedure for an excipient                                                                                                                                                                                                                   | 27/05/2021 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

|           | - Other changes to a test procedure (including replacement or addition)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |            |            |          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0033/G | This was an application for a group of variations. B.II.c.2.d - Change in test procedure for an excipient - Other changes to a test procedure (including replacement or addition) B.II.c.1.b - Change in the specification parameters and/or limits of an excipient - Addition of a new specification parameter to the specification with its corresponding test method B.II.c.z - Change in control of excipients in the Finished Product - Other variation B.II.c.4.a - Change in synthesis or recovery of a non- pharmacopoeial or novel excipient - Minor change B.II.c.z - Change in control of excipients in the | 25/05/2021 | n/a        |          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| II/0023/G | This was an application for a group of variations. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation                                                                                                                                           | 20/05/2021 | 31/05/2021 | Annex II | The MAH has submitted additional validation data, which were a condition to the Marketing Authorisation (Specific Obligation SO3; In order to confirm the consistency of the finished product manufacturing process, the MAH should provide additional validation data. Due date: March 2021). Following assessment of the data, Annex IIE (specific obligation to complete post-authorisation measures for a conditional marketing authorisation) is updated; SO3 is fulfilled and is deleted from the list of specific obligations. |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| IB/0031/G   | This was an application for a group of variations. Sections 6.3 and 6.6 of the SmPC have been updated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 17/05/2021   | 31/05/2021   | SmPC, Labelling and PL   | The SmPC, labelling and package leaflet are updated to extend the shelf life of thawed vials from 5 days to 1 monhts at 2-8Â°C.                                                                                   |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|             | to change the storage conditions of the unopened thawed vial from '5 days at 2-8Â°C' to '1 month at 2- 8Â°C'. An additional text field has been added to the outer packaging to insert the expiry date at 2 to 8Â°C. B.I.z - Quality change - Active substance - Other variation B.II.c.4.a - Change in synthesis or recovery of a non- pharmacopoeial or novel excipient - Minor change B.I.b.1.a - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits for medicinal products subject to OCABR B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.I.b.1.a - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits for medicinal products subject to OCABR B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of |              |              |                          | In addition, section 6.3 of the SmPC is updated in line with CHMP/QWP/159/96 corr. (Note for Guidance of Maximum Shelf-Life for Sterile Products for Human Use After First Opening or Following Reconstitution). |

<div style=\"page-break-after: always\"></div>

|           | conditions of the finished product or the diluted/reconstituted product B.II.f.1.d - Stability of FP - Change in storage conditions of the finished product or the diluted/reconstituted product                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |            |     |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IA/0032   | B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 12/05/2021 | n/a |
| II/0028/G | This was an application for a group of variations. B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch | 07/05/2021 | n/a |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| B.II.b.2.a - Change to importer, arrangements and quality Replacement/addition of control/testing takes place B.II.b.1.b - Replacement manufacturing site for the site B.II.b.2.a - Change to importer, arrangements and quality Replacement/addition of control/testing takes place B.II.d.2.a - Change in test product - Minor changes procedure B.II.b.2.b - Change to importer, arrangements and quality Replacement/addition of control/testing takes place product and any of the biol/immunol method B.II.d.2.d - Change in test product - Other changes (including replacement B.II.b.2.a - Change to importer, arrangements and quality Replacement/addition of control/testing takes place B.II.b.2.b - Change to importer, arrangements and quality Replacement/addition of control/testing takes place   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|           | biol/immunol method B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                                        |            |     |                      |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------------------|
| IB/0029   | B.II.c.z - Change in control of excipients in the Finished Product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 04/05/2021 | n/a |                      |
| II/0027   | B.II.g.2 - Introduction of a post approval change management protocol related to the finished product                                                                                                                                                                                                                                                                                                                                                                                                                                   | 27/04/2021 | n/a |                      |
| II/0022/G | This was an application for a group of variations. B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.4.c - Change in the batch size (including batch size ranges) of the finished product - The change requires assessment of the comparability of a biological/immunological medicinal product or a new | 21/04/2021 | n/a | bioequivalence study |
| II/0026   | B.II.g.2 - Introduction of a post approval change management protocol related to the finished product                                                                                                                                                                                                                                                                                                                                                                                                                                   | 20/04/2021 | n/a |                      |
| IB/0025/G | This was an application for a group of variations. B.II.z - Quality change - Finished product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                         | 20/04/2021 | n/a |                      |

<div style=\"page-break-after: always\"></div>

|           | B.II.c.1.c - Change in the specification parameters and/or limits of an excipient - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.II.c.2.d - Change in test procedure for an excipient - Other changes to a test procedure (including replacement or addition)                                                                                                                                                                                                                                                                                                                                                                                                                     |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0019   | C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required                                                                                                                                                                                                                                                                                                                                                                                                                                         | 15/04/2021 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| II/0016/G | This was an application for a group of variations. Group of two type II variations C.I.3.b consisting of: C.I.3.b - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Change(s) with new additional data submitted by the MAH C.I.3.b - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Change(s) with new additional data submitted by the MAH C.I.3.b - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the | 13/04/2021 | 14/04/2021 | SmPC and PL | This variation pertains to two updates of the section 4.8 of the SmPC to implement the wording agreed by the PRAC following the outcome of the Post Authorisation Measures PAM-MEA-002.1 (EMEA/H/C/005735/MEA/002.1) and PAM- LEG-022 (EMEA/H/C/005735/LEG/022 ). In this context, 2 new adverse drug reactions (ADRs) ('diarrhoea', 'vomiting') were added with very common and common frequencies respectively, and the ADR 'pain in extremity' was updated with a footnote. In addition, the ADR concerning 'hypersensitivity reactions' was further detailed (e.g. 'rash, pruritus, urticaria, angioedema') with the relevant frequency categories. |

<div style=\"page-break-after: always\"></div>

|           | assessment done under A 45/46 - Change(s) with new additional data submitted by the MAH C.I.3.b - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Change(s) with new additional data submitted by the MAH   |            |     |                      |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------------------|
| IB/0024/G | This was an application for a group of variations. B.II.f.1.e - Stability of FP - Change to an approved stability protocol B.II.f.1.e - Stability of FP - Change to an approved stability protocol of FP - Other variation                                                                                                       | 13/04/2021 | n/a | B.II.f.z - Stability |
| II/0020/G | application for a group of variations. B.II.c.z - Change in control of excipients in the Finished Product - Other variation B.II.c.4.a - Change in synthesis or recovery of a non- pharmacopoeial or novel excipient - Minor change B.II.c.z - Change in control of excipients in the Finished Product - Other variation         | 31/03/2021 | n/a | This was an          |
| II/0017/G | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.e.4.c - Change in shape or dimensions of the container or closure (immediate packaging) - Sterile                                                                     | 29/03/2021 | n/a |                      |

<div style=\"page-break-after: always\"></div>

| medicinal products B.II.b.2.b - Change to importer, arrangements and quality Replacement/addition of control/testing takes place product and any of the test biol/immunol method B.II.b.1.c - Replacement manufacturing site for the manufacturing operation(s) release/control, and secondary biol/immunol medicinal products forms manufactured by processes B.II.d.2.a - Change in test product - Minor changes procedure B.II.d.2.a - Change in test product - Minor changes procedure B.II.b.1.b - Replacement manufacturing site for the site B.II.b.2.b - Change to importer, arrangements and quality Replacement/addition of control/testing takes place product and any of the test biol/immunol method B.II.d.2.d - Change in test product - Other changes   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| IB/0021   | B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product                                                                                                                   | 26/03/2021   | n/a        |             |                                                                                                             |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|-------------------------------------------------------------------------------------------------------------|
| II/0018/G | This was an application for a group of variations. B.II.g.2 - Introduction of a post approval change management protocol related to the finished product B.II.g.2 - Introduction of a post approval change management protocol related to the finished product | 26/03/2021   | n/a        |             |                                                                                                             |
| IB/0013   | B.II.f.1.d - Stability of FP - Change in storage conditions of the finished product or the diluted/reconstituted product                                                                                                                                       | 26/03/2021   | 14/04/2021 | SmPC and PL |                                                                                                             |
| IB/0014   | B.I.e.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product                                                                                                                    | 24/03/2021   | 14/04/2021 | Annex II    | Update of Annex II of the product information to include an additional active substance manufacturing site. |
| IB/0015   | B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)                                                                                                                         | 17/03/2021   | n/a        |             |                                                                                                             |
| II/0012   | B.II.b.3.c - Change in the manufacturing process of the finished or intermediate product - The product is a biological/immunological medicinal product and the change requires an assessment of comparability                                                  | 12/03/2021   | n/a        |             |                                                                                                             |
| II/0011/G | This was an application for a group of variations. B.I.a.1.j - Change in the manufacturer of AS or of a                                                                                                                                                        | 09/03/2021   | n/a        |             |                                                                                                             |

<div style=\"page-break-after: always\"></div>

|         | starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test method at the site is a biol/immunol method B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure   |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0009 | B.II.f.1.c - Stability of FP - Change in storage conditions for biological medicinal products, when the stability studies have not been performed in accordance with an approved stability protocol                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 19/02/2021 | 23/02/2021 | SmPC and PL | The SmPC sections 6.3 and 6.6 have been updated to include information related to the transportation of diluted and undiluted product at non-frozen storage conditions and to the handling of temperature excursions once removed from the freezer as follows: Unopened vial; Once removed from the freezer, the unopened vaccine can be stored for up to 5 days at 2 Â°C to 8 Â°C. Within the 5 days shelf-life at 2 Â°C to 8 Â°C, up to 12 hours may be used for transportation. Prior to use, the unopened vaccine can be stored for up to 2 hours at temperatures up to 30 Â°C. Diluted medicinal product; Chemical and physical in-use stability, including during transportation, has been demonstrated for 6 hours at 2 ÂºC to 30 ÂºC after dilution in sodium chloride 9 mg/mL (0.9%) |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                      |            |     | solution for injection. From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions are the responsibility of the user. Handling of temperature excursions once removed from the freezer Stability data indicate that the unopened vial is stable for up to: â¢ 24 hours when stored at temperatures from -3 Â°C to 2 Â°C â¢ a total of 4 hours when stored at temperatures from 8 Â°C to 30 Â°C; this includes the 2 hours at up to 30 Â°C detailed above This information is intended to guide healthcare professionals only in case of temporary temperature excursion.   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0010/G | This was an application for a group of variations. B.II.c.z - Change in control of excipients in the Finished Product - Other variation B.II.c.4.a - Change in synthesis or recovery of a non- pharmacopoeial or novel excipient - Minor change B.II.c.2.a - Change in test procedure for an excipient - Minor changes to an approved test procedure | 22/02/2021 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| II/0008/G | This was an application for a group of variations. B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change                                                                                                                                                                                           | 16/02/2021 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

| in the manufacturing process B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation B.II.b.4.c - Change in the batch size (including batch size ranges) of the finished product - The change requires assessment of the comparability of a   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|         | bioequivalence study B.II.b.4.c - Change in the batch size (including batch size ranges) of the finished product - The change requires assessment of the comparability of a biological/immunological medicinal product or a new bioequivalence study B.II.b.4.c - Change in the batch size (including batch size ranges) of the finished product - The change requires assessment of the comparability of a biological/immunological medicinal product or a new bioequivalence study B.II.b.5.a - Change to in-process tests or limits applied during the manufacture of the finished product - Tightening of in-process limits B.II.c.z - Change in control of excipients in the Finished Product - Other variation   |            |            |             |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|
| II/0005 | B.II.g.2 - Introduction of a post approval change management protocol related to the finished product                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 10/02/2021 | n/a        |             |
| II/0004 | B.I.e.2 - Introduction of a post approval change management protocol related to the AS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 04/02/2021 | n/a        |             |
| IB/0007 | To update the dose interval for Comirnaty in sections 4.2, 5.1 of the SmPC and section 3 and section 'The following information is intended for healthcare professionals only' of the PL to implement the recommendation of the CHMP. The wording of the dose interval in section 4.2 has been updated with a view to reflect better in section 4.2 the evidence from the submitted data and provide more clear guidance as well as to describe                                                                                                                                                                                                                                                                        | 28/01/2021 | 02/02/2021 | SmPC and PL |

<div style=\"page-break-after: always\"></div>

|           | further in section 5.1 the available data underlying this revision. The MAH has also taken the opportunity to introduce a few editorial changes and to provide updated material affected by the change including 'How to prepare and administer poster' and 'Vaccine traceability card' In addition, the company has informed us that they updated the 'Administration video' and the 'Comirnaty website'. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                       |            |     |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IB/0006   | B.II.c.z - Change in control of excipients in the Finished Product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 28/01/2021 | n/a |
| II/0003/G | This was an application for a group of variations. B.II.c.2.d - Change in test procedure for an excipient - Other changes to a test procedure (including replacement or addition) B.II.c.2.d - Change in test procedure for an excipient - Other changes to a test procedure (including replacement or addition) B.II.c.z - Change in control of excipients in the Finished Product - Other variation B.II.c.1.b - Change in the specification parameters and/or limits of an excipient - Addition of a new specification parameter to the specification with its corresponding test method B.II.c.1.c - Change in the specification parameters | 27/01/2021 | n/a |

<div style=\"page-break-after: always\"></div>

|           | and/or limits of an excipient - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.II.c.z - Change in control of excipients in the Finished Product - Other variation B.II.c.z - Change in control of excipients in the Finished Product - Other variation B.II.c.z - Change in control of excipients in the Finished Product - Other variation B.II.c.z - Change in control of excipients in the Finished Product - Other variation B.II.c.z - Change in control of excipients in the Finished Product - Other variation   |            |            |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0001   | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                                                                                                                                                                                                                                                                                                                     | 26/01/2021 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| II/0002/G | This was an application for a group of variations. Grouped variation: B.II.e.5.c - Change in pack size of the finished product - Change in the fill weight/fill volume of sterile multidose (or single-dose, partial use) parenteral medicinal products, including biological/immunological medicinal products B.II.d.1.d - Change in the specification parameters and/or limits of the finished product - Deletion of a non-significant specification parameter                                                                                                           | 08/01/2021 | 08/01/2021 | SmPC, Labelling and PL | The change in pack size and change in specifications were approved. The SmPC sections 2, 4.2, 6.5 6.6 has been updated to reflect the following: One vial (0.45 mL) contains 6 doses of 0.3 mL after dilution. In order to extract six doses from a single vial, low dead-volume syringes and/or needles should be used. The low dead-volume syringe and needle combination should have a dead volume of no more than 35 microliters. If standard syringes and needles are used, there may not be enough of the vaccine to extract a sixth dose from a vial. If the amount of vaccine remaining in the vial after the fifth dose cannot provide a full dose (0.3 ml), the healthcare |

<div style=\"page-break-after: always\"></div>

| B.II.d.1.c - Change in the specification parameters and/or limits of the finished product - Addition of a new specification parameter to the specification with its corresponding test method B.II.d.1.d - Change in the specification parameters and/or limits of the finished product - Deletion of a non-significant specification parameter B.II.d.1.c - Change in the specification parameters and/or limits of the finished product - Addition of a new specification parameter to the specification with its corresponding test method B.II.e.5.c - Change in pack size of the finished product - Change in the fill weight/fill volume of sterile multidose (or single-dose, partial use) parenteral medicinal products, including biological/immunological medicinal products   | professional must discard the vial and its contents. There should be no pooling from multiple vials to make up a full dose, and any unused vaccine should be discarded 6 hours after dilution. The Labelling and PL have been updated accordingly.   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|